Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
0874Company Overview
The company was approved by the National Economic System Reform Commission in Document No. 139 of Physical Reform [1997], and was exclusively initiated by Guangzhou Pharmaceutical Group Co., Ltd., and established as a sponsor after restructuring its 8 traditional Chinese medicine manufacturing enterprises and 3 pharmaceutical trading enterprises and investing in state-owned assets related to production and operation assets. It is mainly engaged in asset management, investment, development, and capital financing, and is engaged in the development and production of proprietary Chinese medicines, the production of biological products, health pharmaceuticals, and health beverages, and the wholesale, retail, import and export of traditional Chinese medicines, Western medicines, and medical devices. The company is mainly engaged in (1) research and development, manufacturing and sales of proprietary Chinese and Western medicines, chemical raw materials, natural medicines, biomedicine, and chemical raw material intermediates; (2) wholesale, retail and import and export business of Western medicines, traditional Chinese medicines and medical devices; (3) R&D, production and sales of major health products; and (4) investment in health industries such as medical services, health management, and health care. The main products of the company are thirst quencher pills, Xia Sangju, Wuji Baifeng pills, Huatuo reformed pills, chuanbei loquat cream, Qingkailing oral liquid, Xiaochaihu infusion, etc. The main products of Western medicine manufacturers are chemical preparations such as ceftriamidine and amoxicillin, chemical raw materials such as ceftriaxone, etc., and the main products of prepackaged food manufacturers are Wang Laoji herbal tea, etc. During the reporting period, the Group and its joint ventures obtained a total of 11 production approvals and passed 6 compliance evaluation specifications. A total of 85 patents have been applied for, including 71 invention patents and 14 utility models; 60 authorized patents, 40 invention patents, and 20 utility model patents have been granted.
Shariah Compliance Benchmarks:
- Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
- Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
This stock does not meet all Shariah compliance criteria according to AAOIFI standards.
| Name | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited |
| Ticker | 0874 |
| Main Business | Drug Manufacturers—Specialty & Generic |
| Type | Common Stock |
| Industry | Drug Manufacturers—Specialty & Generic |
| Country | HK |
| Market Cap | $4.55 B |
Shariah Analysis Breakdown
| Revenue Segment | Value ($M) | Non-Compliant ($M) | Reason |
|---|---|---|---|
| Big business | $26,310.0 | $0.0 | - |
| Great health | $7,050.0 | $0.0 | - |
| Daonan medicine | $6,350.0 | $0.0 | - |
| Other | $260.7 | $0.0 | - |
| Interest income | $626.8 | $626.8 | - |
| Total | $40,597.5 | $626.8 | 1.52% (passed) |
| Liability Item | Value ($M) | % of Market Cap |
|---|---|---|
| short term borrowing | $1,092,436,974.8 | 24.04% |
| notes payable | $537,815,126.1 | 11.83% |
| long term bank loan | $464,985,994.4 | 10.23% |
| Total Interest-Bearing Debt | $2,095,238,095.2 | 46.10% |
| Market Capitalization | $4,545,192,307.7 | 100.00% |
| Compliance Status | Threshold: 33% | failed |